IL-23R rs11209026 polymorphism modulates IL-17A expression in patients with rheumatoid arthritis

Academic Article

Abstract

  • The interleukin (IL)-17/IL-23 axis is an important pro-inflammatory pathway in rheumatoid arthritis (RA). IL-23 maintains CD4 + T-helper 17 (Th 17) cells, whereas IL-12 negates IL-17A production by promoting Th 1-cell differentiation. We sought evidence for any effect of polymorphisms within the interleukin-23 receptor (IL-23R), IL-12 or IL-21 genes on serum cytokine concentrations in 81 patients with RA. Serum cytokines were measured using bead-based multiplex assays. Targeted cytokines were detected in up to 66% of samples. A subgroup of 48 patients had detectable serum IL-17A. Within this subgroup, patients, homozygous for the IL-23R rs11209026 major allele had significantly higher serum IL-17A concentrations compared with patients with the minor allele (394.51±529.72 pg ml -1 vs 176.11±277.32 pg ml -1; P=0.017). There was no significant difference in any of the cytokine concentrations examined in patients positive for the minor allele vs homozygosity for the major allele of IL-12B rs3213337, IL-12Bpro rs17860508 and IL-21 rs6822844. Our results suggest the IL-23R Arg381Gln substitution may influence serum IL-17A concentrations. In patients with the 381Gln allele higher IL-23 concentrations may be needed to produce similar IL-17A concentrations to those in patients with the 381Arg allele. This suggests altered IL-23R function in patients with the minor allele and warrants further functional studies. © 2012 Macmillan Publishers Limited All rights reserved.
  • Authors

    Published In

  • Genes and Immunity  Journal
  • Digital Object Identifier (doi)

    Author List

  • Hazlett J; Stamp LK; Merriman T; Highton J; Hessian PA
  • Start Page

  • 282
  • End Page

  • 287
  • Volume

  • 13
  • Issue

  • 3